Similar articles for PMID: 29437771

Year	Number of Results
1981	1
1992	1
1994	2
1995	1
1996	1
2000	1
2003	1
2009	1
2012	6
2013	10
2014	16
2015	20
2016	10
2017	12
2018	12
2019	9
2020	2
2021	1
2024	0

1

Hepatotoxicity Associated With Vismodegib.

Bedi PS, Rai MP, Tageja N, Laird-Fick H. Bedi PS, et al. BMJ Case Rep. 2018 Feb 8;2018:bcr2017222969. doi: 10.1136/bcr-2017-222969. BMJ Case Rep. 2018. PMID: 29437771 Free PMC article.

2

Hepatotoxicity Associated With Vismodegib: Could Dose Reduction Be an Effective Management?

de Perosanz-Lobo D, Burgos-Blasco P, Moreno-Arrones OM, Bea-Ardebol S. de Perosanz-Lobo D, et al. Dermatol Surg. 2021 Jul 1;47(7):1006-1007. doi: 10.1097/DSS.0000000000002924. Dermatol Surg. 2021. PMID: 34167133 No abstract available.

3

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Basset-Seguin N, et al. Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981813 Clinical Trial.

4

Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.

Ash MM, Jolly PS. Ash MM, et al. Int J Dermatol. 2015 Mar;54(3):370-4. doi: 10.1111/ijd.12543. Epub 2014 Jul 11. Int J Dermatol. 2015. PMID: 25039741 Review.

5

Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.

Scalvenzi M, Villani A, Costa C, Cappello M. Scalvenzi M, et al. Dermatol Ther. 2019 Jul;32(4):e12971. doi: 10.1111/dth.12971. Epub 2019 Jun 12. Dermatol Ther. 2019. PMID: 31124200 No abstract available.

6

Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.

Woltsche N, Pichler N, Wolf I, Di Meo N, Zalaudek I. Woltsche N, et al. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e144-e145. doi: 10.1111/jdv.15367. Epub 2018 Dec 17. J Eur Acad Dermatol Venereol. 2019. PMID: 30472793 No abstract available.

7

Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.

Edwards BJ, Raisch DW, Saraykar SS, Sun M, Hammel JA, Tran HT, Wehr N, Arabyat R, West DP. Edwards BJ, et al. Drugs R D. 2017 Mar;17(1):211-218. doi: 10.1007/s40268-016-0168-2. Drugs R D. 2017. PMID: 28063021 Free PMC article.

8

Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.

Routt E, Ratner D. Routt E, et al. Dermatol Surg. 2020 Aug;46(8):1109-1112. doi: 10.1097/DSS.0000000000001985. Dermatol Surg. 2020. PMID: 31274526 No abstract available.

9

Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency.

Maul LV, Kähler KC, Hauschild A. Maul LV, et al. JAMA Dermatol. 2016 Dec 1;152(12):1387-1388. doi: 10.1001/jamadermatol.2015.4592. JAMA Dermatol. 2016. PMID: 26720040 No abstract available.

10

Vismodegib (Erivedge) for basal cell carcinoma.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4. Med Lett Drugs Ther. 2012. PMID: 22777303 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year